ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CNTA Centessa Pharmaceuticals PLC

8.99
0.09 (1.01%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Centessa Pharmaceuticals PLC NASDAQ:CNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.09 1.01% 8.99 8.82 9.50 9.00 8.75 8.83 185,144 01:00:00

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

21/05/2024 1:45pm

GlobeNewswire Inc.


Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Centessa Pharmaceuticals Charts.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Jefferies Global Healthcare Conference Date: June 6, 2024Location: NY, NYFireside Chat: 1:00 PM ET

Event: Goldman Sachs 45th Annual Global Healthcare ConferenceDate: June 11, 2024Location: Miami, FLFireside Chat: 11:20 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.

About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.

Contact:Kristen K. Sheppard, Esq.SVP of Investor Relationsinvestors@centessa.com

1 Year Centessa Pharmaceuticals Chart

1 Year Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart